FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s DS-8201 for HER2-Positive Metastatic Breast Cancer FDA Grants Breakthrough Therap Wednesday August 30th, 2017By Tokio X'press FDA, JPN Daiichi Sankyo
Bristol-Myers Squibb and Daiichi Sankyo Announce Research Collaboration to Evaluate Opdivo® (nivolumab) and DS-8201 in HER2-Expressing Breast and Bladder Cancers Bristol-Myers Sq Tuesday August 29th, 2017By Tokio X'press JPN, Pharmaceutical, USA Daiichi Sankyo
